Carbidopa/levodopa (WD-1603) vs Levodopa/carbidopa (ND0612)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Parkinson's Disease

Shared mechanism: dopamine precursor · full Parkinson's Disease pipeline

Carbidopa/levodopa (WD-1603)

Developed by Hong Kong WD Pharmaceutical Co., Limited

Phase 2 in Parkinson's Diseasesmall molecule
Partial signal

NCT05036473 · Phase 2 · completed

This randomized, double-blind, placebo-controlled Phase 2 trial in early Parkinson's disease enrolled only 40 patients across three dose groups and placebo. All three doses of WD-1603 produced a statistically significant improvement in combined motor and daily-living function scores versus placebo at 27 days, with the largest effect at the highest dose (p=0.0003), but the very small sample size means these results need confirmation in a larger trial.

Reported efficacy

To compare the changes from the baseline mean value before the study to the mean value on the 27th day of the study between each dose group and the placebo group. (27 days- from the baseline to the 27th day): Day 27 MDS-UPDRS II+III total score, LS mean change from baseline vs placebo: low dose -6.7 (p=0.0388); medium dose -8.5 (p=0.0125); high dose -13.6 (p=0.0003) (met)

Result source: NCT05036473

Levodopa/carbidopa (ND0612) · Onerji

Marketed by NeuroDerm Ltd.

Phase 3 in Parkinson's Diseasesmall molecule
Partial signal

NCT02577523 · Phase 2 · completed

Participants were randomized to two ND0612 regimens, but the study was only single-blinded for outcome assessors, had no placebo or active-control arm, and was small with 19 participants per group. The clinical primary endpoint was daily OFF time; although the 24-hour regimen showed a numerically greater reduction, statistical significance for the comparison was not reported, so the result is unclear.

Reported efficacy

Change in Daily "OFF" Time (Baseline to Day 28): Change in Daily "OFF" Time (Baseline to Day 28): ND0612 Regimen 1 - 24-hr Infusion -2.8 Hours (95% CI -4.6--0.9) vs ND0612 Regimen 2 - 14-hr Infusion -1.3 Hours (95% CI -3.1-0.5) (unclear)

Result source: NCT02577523

Results for Parkinson's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.

Key endpointCarbidopa/​levodopa (WD-1603)Levodopa/​carbidopa (ND0612)
OFF time, change—Not reported-2.1 vs -1.4−0.7 vs placebowk 2 · n 19NCT01883505
ON time without troublesome dyskinesia, change—Not reported—Trial running · NCT04006210
UPDRS Part III, change—Not reported—Trial running · NCT04006210
MDS-UPDRS Part II, change—Not reported—Trial running · NCT04006210

OFF time, change

Carbidopa/​levodopa (WD-1603)
—Not reported
Levodopa/​carbidopa (ND0612)
-2.1 vs -1.4−0.7 vs placebowk 2 · n 19NCT01883505

ON time without troublesome dyskinesia, change

Carbidopa/​levodopa (WD-1603)
—Not reported
Levodopa/​carbidopa (ND0612)
—Trial running · NCT04006210

UPDRS Part III, change

Carbidopa/​levodopa (WD-1603)
—Not reported
Levodopa/​carbidopa (ND0612)
—Trial running · NCT04006210

MDS-UPDRS Part II, change

Carbidopa/​levodopa (WD-1603)
—Not reported
Levodopa/​carbidopa (ND0612)
—Trial running · NCT04006210
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Carbidopa/levodopa (WD-1603): 0 of 4 rows · Levodopa/carbidopa (ND0612): 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricCarbidopa/​levodopa (WD-1603)Levodopa/​carbidopa (ND0612)
Dropout rate—
—24-hr Infusiona
NCT02577523 · Phase 2
show 4 more results
—14-hr Infusion
NCT02577523 · Phase 2
0%Period 1. ND0612
NCT01883505 · Phase 2 · registry result, not featured evidence
—Period 2. ND0612
NCT01883505 · Phase 2 · registry result, not featured evidence
—Period 2. ND0612 + Entacapone
NCT01883505 · Phase 2 · registry result, not featured evidence · combination
Discontinued due to AEs—
—24-hr Infusiona
NCT02577523 · Phase 2
show 4 more results
—14-hr Infusion
NCT02577523 · Phase 2
—Period 1. ND0612
NCT01883505 · Phase 2 · registry result, not featured evidence
—Period 2. ND0612
NCT01883505 · Phase 2 · registry result, not featured evidence
—Period 2. ND0612 + Entacapone
NCT01883505 · Phase 2 · registry result, not featured evidence · combination
Serious AEs—
10.5%24-hr Infusiona
NCT02577523 · Phase 2
show 4 more results
10.5%14-hr Infusion
NCT02577523 · Phase 2
5.3%Period 1. ND0612
NCT01883505 · Phase 2 · registry result, not featured evidence
0%Period 2. ND0612
NCT01883505 · Phase 2 · registry result, not featured evidence
0%Period 2. ND0612 + Entacapone
NCT01883505 · Phase 2 · registry result, not featured evidence · combination
Most frequent reported AEs—
24-hr Infusiona
infusion site nodule 57.9%
infusion site erythema 26.3%
infusion site bruising 21.1%
NCT02577523 · Phase 2
show 4 more results
14-hr Infusion
infusion site nodule 36.8%
infusion site bruising 15.8%
infusion site haemorrhage 15.8%
NCT02577523 · Phase 2
fatigue 10.5% (placebo 0%)
headache 10.5% (placebo 9.1%)
abdominal pain lower 5.3% (placebo 0%)
NCT01883505 · Phase 2 · registry result, not featured evidence
blood creatinine abnormal 12.5% (placebo 0%)
dental caries 12.5% (placebo 0%)
diarrhoea 12.5% (placebo 0%)
NCT01883505 · Phase 2 · registry result, not featured evidence
back pain 12.5% (placebo 0%)
pain in extremity 12.5% (placebo 9.1%)
abdominal pain lower 0% (placebo 0%)
NCT01883505 · Phase 2 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Carbidopa/levodopa (WD-1603)

MDS-UPDRS II III -6.7 score @ 3.857142857142857wk
absolute change · score
No placebo or comparator arm
NCT05036473 · Phase 2 · sponsor-reported, not registry data
show 2 more results
-8.5 score @ 3.857142857142857wk
NCT05036473 · Phase 2 · sponsor-reported, not registry data
-13.6 score @ 3.857142857142857wk
NCT05036473 · Phase 2 · sponsor-reported, not registry data

Levodopa/carbidopa (ND0612)

OFF Time -2.8 hours @ 4wk24-hr Infusion
absolute change · hours
No placebo or comparator arm
NCT02577523 · Phase 2
show 1 more result
-1.3 hours @ 4wk14-hr Infusion
NCT02577523 · Phase 2
Good ON" Time 3.7 hours @ 4wk24-hr Infusion
absolute change · hours
No placebo or comparator arm
NCT02577523 · Phase 2
show 1 more result
2.8 hours @ 4wk14-hr Infusion
NCT02577523 · Phase 2
UPDRS Part 3 Motor -19.1 score @ 4wk24-hr Infusion
absolute change · score
No placebo or comparator arm
NCT02577523 · Phase 2
show 1 more result
-10.7 score @ 4wk14-hr Infusion
NCT02577523 · Phase 2
UPDRS Part 2 ADL -2.9 score @ 4wk24-hr Infusion
absolute change · score
No placebo or comparator arm
NCT02577523 · Phase 2
show 1 more result
-1.9 score @ 4wk14-hr Infusion
NCT02577523 · Phase 2
CGI-I 52.6% (n=19) @ 0.43wk24-hr Infusion
event count · % of participants
No placebo or comparator arm
Day 3: Subjects with improvements
NCT02577523 · Phase 2 · converted to % from 10 Participants as posted
show 1 more result
47.4% (n=19) @ 0.43wk*14-hr Infusion
Day 3: Subjects with improvements
NCT02577523 · Phase 2 · converted to % from 9 Participants as posted
CGI-I 73.7% (n=19) @ 4wk24-hr Infusion
event count · % of participants
No placebo or comparator arm
Day 28: Subjects with improvements
NCT02577523 · Phase 2 · converted to % from 14 Participants as posted
show 1 more result
68.4% (n=19) @ 4wk*14-hr Infusion
Day 28: Subjects with improvements
NCT02577523 · Phase 2 · converted to % from 13 Participants as posted
PDSS-2 -4.1 score @ 3.857wk24-hr Infusion
absolute change · score
No placebo or comparator arm
NCT02577523 · Phase 2
show 1 more result
-0.8 score @ 3.857wk14-hr Infusion
NCT02577523 · Phase 2
PDQ-39 Summary Index -7.5 score @ 3.857wk24-hr Infusion
absolute change · score
No placebo or comparator arm
NCT02577523 · Phase 2
show 1 more result
-3.7 score @ 3.857wk14-hr Infusion
NCT02577523 · Phase 2
OFF Time -2.1 vs -1.4 placebo hours @ 2wk
absolute change · hours
NCT01883505 · Phase 2 · registry result, not featured evidence
UPDRS Total -11.7 vs -9.3 placebo score @ 2wk
absolute change · score
NCT01883505 · Phase 2 · registry result, not featured evidence
PDSS -17.1 vs -0.5 placebo score @ 2wk
absolute change · score
NCT01883505 · Phase 2 · registry result, not featured evidence
PDQ-39 -6.6 vs -1.8 placebo score @ 2wk
absolute change · score
NCT01883505 · Phase 2 · registry result, not featured evidence

+ 1 further endpoint in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Carbidopa/levodopa (WD-1603)'s landscape · Levodopa/carbidopa (ND0612)'s landscape